Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02756572 · ClinicalTrials.gov registry record · Phase 2
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT02756572 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 30 participants.
The verdict
NCT02756572, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This clinical trial studies how well early stem cell transplantation works in treating patients with high-grade myeloid neoplasms that has come back after a period of improvement or does not respond to treatment. Drugs used in chemotherapy, such as filgrastim, cladribine, cytarabine and mitoxantrone hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a donor peripheral blood cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells. Early stem cell transplantation may result in more successful treatment for patients with high-grade myeloid neoplasms.
Interventions
- DRUG Cladribine
- DRUG Cytarabine
- BIOLOGICAL Filgrastim
- DRUG Fludarabine Phosphate
- DRUG Cyclosporine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-09-22 |
| Est. Completion | 2020-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02756572
The ClinicalTrials.gov registry entry for NCT02756572 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cladribine is the first listed.
NCT02756572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02756572 about?
NCT02756572 is a clinical study titled "Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms". This clinical trial studies how well early stem cell transplantation works in treating patients with high-grade myeloid neoplasms that has come back after a period of improvement or does not respond to treatment. Drugs used in chemotherapy, such as filgrastim, cladribine, cytarabine and mitoxantrone...
What is the current status of trial NCT02756572?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2016-09-22. Estimated completion is 2020-07-01.
What interventions are being tested in trial NCT02756572?
The interventions under investigation include: Cladribine (DRUG), Cytarabine (DRUG), Filgrastim (BIOLOGICAL), Fludarabine Phosphate (DRUG), Cyclosporine (DRUG).
Who is sponsoring clinical trial NCT02756572?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.